EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Association of Chemokine (C-C Motif) Receptor 5 and Ligand 5 with Recovery from Major Depressive Disorder and Related Neurocognitive Impairment

Olivia Bauer, Vladimir M Milenkovic, Sven Hilbert, Nina Sarubin, Johannes Weigl, Lisa-Marie Bahr, Thomas C Wetter, Barbara Heckel, Christian H Wetzel, Rainer Rupprecht, Caroline Nothdurfter

Neuroimmunomodulation · 2020 · 27 (3) · 152-162

DOI: 10.1159/000513093 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neuroimmunomodulation, online erschienen am 27.01.2021. Verfasst von Olivia Bauer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Chemokine CCL5, Major Depressive Disorder, Receptors, CCR5. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Inflammatory processes play an important role in the pathophysiology of major depressive disorder (MDD), but their relevance for specific symptoms such as neurocognitive impairment is rarely investigated.

Methods

In this observational study, we investigated the changes of leukocyte chemokine (C-C motif) receptor 5 (CCR5) and ligand 5 (CCL5) mRNA levels and inflammatory cytokines in 60 MDD patients before (PRE) and after 5 weeks (W5) of antidepressive treatment in relation to therapy response and alterations in cognitive functions by means of the Cambridge Neuropsychological Test Automated Battery (CANTAB). We hypothesized that elevated CCR5 and CCL5 levels in depressed patients would decrease upon treatment and could differ with regard to cognitive impairment associated with MDD.

Results

Both CCR5 and CCL5 levels were significantly decreased in the responder group compared to nonresponders even before treatment. The cytokine IL-6 as a marker of inflammation in depression did not show a difference before treatment in future responders versus nonresponders, but decreased significantly upon antidepressive therapy. Regarding neurocognitive impairment in MDD patients, an increased misperception of the emotion “anger” after 5 weeks of treatment proved to be associated with a more pronounced change in CCR5, and the perception of the emotion “disgust” became faster along with a stronger decrease in CCL5 over the same time. Executive functions typically impaired in MDD patients were not markedly associated with alterations in CCR5/CCL5.

Discussion

CCR5 and CCL5 are important in the targeting of immune cells by HIV. This is the first study providing valuable hints that both CCR5 and CCL5 might also serve as markers of therapy response prediction in MDD. Regarding neurocognitive impairment in depression, CCR5 and CCL5 did not reveal characteristic changes upon MDD treatment such as executive functions, which are probably delayed. However, changes of emotional perception appear to be an earlier responding feature.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokine CCL5Major Depressive DisorderReceptors, CCR5Cognitive DysfunctionHumansLigands

Stichwörter der Autor:innen

Cambridge Neuropsychological Test Automated BatteryChemokine (C-C motif) ligand 5/RANTESChemokine (C-C motif) receptor 5Cognitive impairmentMajor depressive disorder

Substanzen

CCL5 protein, humanCCR5 protein, humanChemokine CCL5LigandsReceptors, CCR5

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.
  • Faculty of Human Sciences, University of Regensburg, Regensburg, Germany.
  • Hochschule Fresenius, University of Applied Sciences, Munich, Germany.
  • Department of Psychology, Psychological Methods and Assessment, Ludwig-Maximilians-Universität, Munich, Germany.
  • Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany, caroline.nothdurfter@medbo.de.

Zitieren

APA

Bauer, O., Milenkovic, V. M., Hilbert, S., Sarubin, N., Weigl, J., Bahr, L. M., Wetter, T. C., Heckel, B., Wetzel, C. H., Rupprecht, R., & Nothdurfter, C. (2020). Association of Chemokine (C-C Motif) Receptor 5 and Ligand 5 with Recovery from Major Depressive Disorder and Related Neurocognitive Impairment. Neuroimmunomodulation, 27(3), 152-162. https://doi.org/10.1159/000513093

Vancouver

Bauer O, Milenkovic VM, Hilbert S, Sarubin N, Weigl J, Bahr LM, et al. Association of Chemokine (C-C Motif) Receptor 5 and Ligand 5 with Recovery from Major Depressive Disorder and Related Neurocognitive Impairment. Neuroimmunomodulation. 2020;27(3):152-162. doi:10.1159/000513093

BibTeX
@article{Bauer2020,
  author = {Bauer, Olivia and Milenkovic, Vladimir M and Hilbert, Sven and Sarubin, Nina and Weigl, Johannes and Bahr, Lisa-Marie and Wetter, Thomas C and Heckel, Barbara and Wetzel, Christian H and Rupprecht, Rainer and Nothdurfter, Caroline},
  title = {Association of Chemokine (C-C Motif) Receptor 5 and Ligand 5 with Recovery from Major Depressive Disorder and Related Neurocognitive Impairment},
  journal = {Neuroimmunomodulation},
  year = {2020},
  volume = {27},
  number = {3},
  pages = {152--162},
  doi = {10.1159/000513093}
}
Kostenlos starten →